Arch Biopartners Inc., a clinical stage company targeting acute organ inflammation with novel therapeutics, has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the company’s drug candidates.
 
Dr. Luke previously held a variety of positions in the pharma industry, including approximately twenty years at Pfizer Inc, where he was a Senior Medical Director, responsible for planning and executing human trials in the areas of infectious diseases, oncology, immunology, cardiology, neurology and pain.
 
After leaving Pfizer in 2011, Dr. Luke continued to hold clinical leadership positions in the pharmaceutical industry. He was most recently Senior Medical Director of Clinical and Scientific Affairs at Target Health Inc.
 
In 2020, Dr. Luke joined the Arch team as a consultant where he played an instrumental role in helping the Company plan and execute the phase II trial for LSALT peptide, targeting complications of COVID-19 in hospitalized patients.
 
“On behalf of the Arch team, we are looking forward to working with Dr. Luke to help guide LSALT peptide toward an additional human trial targeting inflammation related acute kidney injury. His deep clinical experience and broad network in the pharma industry will be a major asset for the Company as we continue to pursue drug approval and commercial opportunities,” said Richard Muruve, CEO of Arch Biopartners.